37 participants
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-10-13
- Start Date:
- 2021-10-15
- Completion:
- 2023-10-15
Conditions
- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
Interventions
- DRUG
No Results Yet